1 week Ago By ABMN Staff
HC Wainwright reissued their buy rating on shares of Vanda Pharmaceuticals ( NASDAQ:VNDA – Free Report ) in a research note published on Monday, Benzinga reports. The firm currently has a $18.00 price target on the biopharmaceutical company’s stock.
Separately, StockNews.com initiated coverage on shares of Vanda Pharmaceuticals in a research report on Thursday, December 19th. They set a “hold” rating for the company.
Check Out Our Latest Stock Report on Vanda Pharmaceuticals Vanda Pharmaceuticals Stock Down 2.1 % Insider Buying and Selling at Vanda Pharmaceuticals In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $5.
17, for a total transaction of $25,850.00. Following the sale, the director now owns 44,857 shares in the company, valued at approximately $231,910.
69. This trade represents a 10.03 % decrease in their position.
The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website . 8.90% of the stock is currently owned by corporate insiders.
Institutional Trading of Vanda Pharmaceuticals Hedge funds and other institutional investors have recently modified their holdings of the company. Meeder Asset Management Inc. bought a new position in Vanda Pharmaceuticals in the 2nd quarter worth $39,000.
ORG Wealth Partners LLC purchased a new position in shares of Vanda Pharmaceuticals in the third quarter valued at about $40,000. SG Americas Securities LLC bought a new position in shares of Vanda Pharmaceuticals in the second quarter worth about $61,000. China Universal Asset Management Co.
Ltd. grew its position in shares of Vanda Pharmaceuticals by 64.0% during the third quarter.
China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 4,374 shares in the last quarter.
Finally, XTX Topco Ltd bought a new stake in Vanda Pharmaceuticals during the 2nd quarter valued at approximately $75,000. 88.14% of the stock is owned by hedge funds and other institutional investors.
About Vanda Pharmaceuticals ( Get Free Report ) Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Further Reading Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
